Integer Holdings Corporation operates as a critical, albeit often invisible, cog in the vast machinery of modern healthcare, functioning as one of the world's largest medical device contract development and manufacturing organizations (CDMOs). While patients thank the doctors and the brand on the box, Integer is the meticulous craftsman behind the scenes, fabricating the intricate components and complete systems that empower those life-saving devices. They are the hidden hands meticulously crafting the hardware that gets implanted or used to "upgrade" the human body, ensuring the internal plumbing and wiring of our biological machines function flawlessly.

Operating within the specialized surgical and medical instrument manufacturing sector, Integer's business model is purely business-to-business, relying on long-term partnerships with major medical device Original Equipment Manufacturers (OEMs). Their extensive product portfolio spans the Cardio & Vascular market, producing components for everything from coronary stents to guidewires, and the Cardiac Rhythm Management & Neuromodulation segment, where they supply critical parts like batteries, capacitors, and lead systems for pacemakers and neurostimulators. Beyond internal human upgrades, they also contribute to Advanced Surgical, Orthopedics, and Portable Medical devices, even dabbling in high-end non-medical batteries for military and environmental applications – because even a drone needs a good heart, apparently.

With manufacturing facilities strategically scattered across the United States, Mexico, Uruguay, Ireland, Malaysia, and the Dominican Republic, Integer serves a global clientele, ensuring that medical innovation is truly a worldwide endeavor. Their competitive edge stems from being a leading CDMO, boasting industry-leading engineering prowess, a relentless commitment to quality (especially crucial when your product is literally inside someone), and high switching costs for customers due to stringent regulatory hurdles and established trust. However, even the most precise engineers face turbulence; the company has been embroiled in class action lawsuits alleging that it misled investors regarding demand for its electrophysiology (EP) devices, leading to a significant stock drop in late 2025. More recently, in a twist befitting a corporate drama, Integer announced in August 2026 its pending acquisition by investment firm KKR, signaling a transition from public scrutiny to private ownership.